Pds biotech reports an inducement grant under nasdaq listing rule 5635(c)(4)

Florham park, n.j., oct. 07, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that pds biotech granted nonstatutory stock options to rory cullinane, pds biotech's vice president, quality assurance, to purchase 70,000 shares of pds biotech common stock as a material inducement to his employment with pds biotech and in accordance with nasdaq listing rule 5635(c)(4) and pds biotech's 2019 inducement plan, as amended.
PDSB Ratings Summary
PDSB Quant Ranking